inclusion criteria: 1. male or female, ≥ 18 years old 2. diagnosed with covid-19, as evaluated by laboratory diagnostic test or diagnosis based on radiological clinical findings. 3. baseline severity categorization of severe or critical covid-19 infection per fda guidance for developing drugs and biological products for covid-19 (february 2021): 1. severe covid-19: * symptoms suggestive of severe systemic illness with covid-19, which could include shortness of breath or respiratory distress * clinical signs indicative of severe systemic illness with covid-19, such as respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air at or pao2/fio2 \< 300 2. critical covid-19: * oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced cannula at flow rates \> 20 l/min with fraction of oxygen ≥ 0.5) or * non-invasive mechanical or endotracheal mechanical ventilation 4. informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: 1. male or female, ≥ 18 years old 2. diagnosed with covid-19, as evaluated by laboratory diagnostic test or diagnosis based on radiological clinical findings. 3. baseline severity categorization of severe or critical covid-19 infection per fda guidance for developing drugs and biological products for covid-19 (february 2021): 1. severe covid-19: * symptoms suggestive of severe systemic illness with covid-19, which could include shortness of breath or respiratory distress * clinical signs indicative of severe systemic illness with covid-19, such as respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air at or pao2/fio2 \< 300 2. critical covid-19: * oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced cannula at flow rates \> 20 l/min with fraction of oxygen ≥ 0.5) or * non-invasive mechanical or endotracheal mechanical ventilation 4. informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: male or female, ≥ 18 years old diagnosed with covid-19, as evaluated by laboratory diagnostic test or diagnosis based on radiological clinical findings. baseline severity categorization of severe or critical covid-19 infection per fda guidance for developing drugs and biological products for covid-19 (february 2021): severe covid-19: symptoms suggestive of severe systemic illness with covid-19, which could include shortness of breath or respiratory distress clinical signs indicative of severe systemic illness with covid-19, such as respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air at or pao2/fio2 < 300 critical covid-19: oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced cannula at flow rates > 20 l/min with fraction of oxygen ≥ 0.5) or non-invasive mechanical or endotracheal mechanical ventilation informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: male or female, ≥ 18 years old diagnosed with covid-19, as evaluated by laboratory diagnostic test or diagnosis based on radiological clinical findings. baseline severity categorization of severe or critical covid-19 infection per fda guidance for developing drugs and biological products for covid-19 (february 2021): severe covid-19: symptoms suggestive of severe systemic illness with covid-19, which could include shortness of breath or respiratory distress clinical signs indicative of severe systemic illness with covid-19, such as respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air at or pao2/fio2 < 300 critical covid-19: oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced cannula at flow rates > 20 l/min with fraction of oxygen ≥ 0.5) or non-invasive mechanical or endotracheal mechanical ventilation informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: 1. male or female, ≥ 18 years old 2. diagnosed with covid-19, as evaluated by laboratory diagnostic test or diagnosis based on radiological clinical findings. 3. baseline severity categorization of severe or critical covid-19 infection per fda guidance for developing drugs and biological products for covid-19 (february 2021): 1. severe covid-19: - symptoms suggestive of severe systemic illness with covid-19, which could include shortness of breath or respiratory distress - clinical signs indicative of severe systemic illness with covid-19, such as respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air at or pao2/fio2 < 300 2. critical covid-19: - oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced cannula at flow rates > 20 l/min with fraction of oxygen ≥ 0.5) or - non-invasive mechanical or endotracheal mechanical ventilation 4. informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: 1. male or female, ≥ 18 years old 2. diagnosed with covid-19, as evaluated by laboratory diagnostic test or diagnosis based on radiological clinical findings. 3. baseline severity categorization of severe or critical covid-19 infection per fda guidance for developing drugs and biological products for covid-19 (february 2021): 1. severe covid-19: - symptoms suggestive of severe systemic illness with covid-19, which could include shortness of breath or respiratory distress - clinical signs indicative of severe systemic illness with covid-19, such as respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air at or pao2/fio2 < 300 2. critical covid-19: - oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced cannula at flow rates > 20 l/min with fraction of oxygen ≥ 0.5) or - non-invasive mechanical or endotracheal mechanical ventilation 4. informed consent obtained from the patient or the patient's legal representative.